previous 3 months, gave informed consent and entered a double-blind levamisole-placebo trial. The levamisole dosage was 50 mg twice a day for 4, consecutive days each week. After 16 weeks the code was broken and the placebo group then received levamisole. One patient on placebo discontinued treatment prior to taking levamisole, leaving 29 patients as the basis for this report. The protocol allowed dosage adjustment after 16 weeks of treatment. The dose was usually decreased if the patient improved or developed an adverse effect, or increased if there was an inadequate clinical response. Clinical examinations were performed at the beginning, 2 weeks, 4 weeks, and every 4 weeks thereafter. Items recorded included: duration of morning stiffness, grip strength, number of tender joints, number of swollen joints, number and size of subcutaneous nodules, and physician's and patient's subjective opinion of overall improvement and possible untoward effects. A Westergren sedimentation rate (ESR), C-reactive protein (CRP), chemical profile (SMA 12) , and urine analysis were obtained at each visit.
Lymphocyte transformation tests were performed in triplicate with PHA (PHA-P, Difco), 1-500, 1-100, and 1-50.4 x 105 mononuclear cells separated on a Ficoll-Hypaque gradient (LSM Biometrics, Rockville, Md.) were cultured in flat bottomed micro wells (Costar) in RPMI (Hepes) and 9 % autologous serum. One microcurie 3H-thymidine (5 curies per mM, Amersham-Searle) was added on day 2 and harvested 18 hours later on to filter paper, washed with TCA, and dried. Radioactivity was determined by liquid scintillation counting (Hartzman et al., 1972) . Counts per minute were averaged for each concentration, and PHA stimulation was determined by measuring the area under the dose response curve (Silverman et al., 1976) . PHA stimulation tests were done prior to treatment, after 4 weeks, and again at 16 weeks in 14 patients who had been assigned to the placebo group in the double-blind phase of the study.
Intradermal skin tests were performed at time 0 and again at 16 weeks with 0-1 ml of the following antigens: PPD (5 TU Connought), monilia (Dermatophytin-0, 1-100, Hollister-Stier), histoplasmin (Parke-Davis), and SK-SD (Varidase, 100/25 units per ml, Lederle). Induration and erythema at 48 hours were measured as the mean of two diameters at 900 to each other. Analysis of skin tests included 25 patients.
The life table technique was used to determine the rapidity of response and was constructed by defining a response as a 25 % improvement in any 3 of 6 measurements, a change which was felt to be clinically significant. These included grip strength, number of swollen joints, number of tender joints, ESR, CRP, and subjective improvement. All 29 treated patients contributed to the rate of response illustrated by this method. The same definition was used for the placebo group. The differences in clinical measurements in placebo and levamisole treated patients has been published previously (Runge et al., 1977) .
The significance of differences in various measurements on the same patients before and after treatment was assessed by the paired Student's t test, whereas differences between different groups were assessed with the unpaired t test. In each instance the P value reflects the two-tailed test of significance. The difference in rate of clinical improvement, using the life table analysis format, was assessed by the log rank test (Peto et al., 1977) .
Results
Twenty of 21 patients who finished a 20-week course of levamisole showed clinical improvement, a 95% response rate by life table analysis (Fig. 1) . Improvement began at 2 weeks and reached a plateau at 20 weeks. Fig. 2 illustrates the response rate from the original double-blind trial, comparing the levamisole and placebo treated groups. The placebo group seemed to respond initially: 4 of 13 (Runge et al., 1977) . One patient failed to show benefit and 8 others were unable to complete the 20-week programme owing to side effects (Table 1) . Of 21 patientŝ remaining on the medication beyond 20 weeks 10 more discontinued treatment over the ensuing 40 weeks owing to recurrence of disease or side effects. By 40 to 60 weeks 64% of the patients had discontinued levamisole. Rash, usually pruritic with erythematous macules or urticaria, was the commonest reason for stopping treatment. One patient developed severe erythema multiforme and a second had a rash which closely resembled a previous gold-induced dermatitis. However, patients who had previously developed gold rashes were not likely to develop rash on levamisole.
Six patients discontinued levamisole owing to insufficient benefit. One never responded (primary failure), and 5 others responded initially but then relapsed (secondary failure). In an attempt to overcome the relapse the dosage was increased to 150 mg a day, 4 days a week, but without benefit. One of the patients treated in this manner also developed a rash. The other reasons for stopping treatment include mild leucopenia (WBC, 3200; 65% neutrophils) in one patient at 12 weeks and possible aggravation of dysmenorrhea in another patient at 16 weeks. the least enhancement of skin erythema to SK-SD showed the greatest clinical response to levamisole. The same trend occurred with induration (Table 3) . There was no significant correlation between the intensity of the pretrial skin test response to SK-SD and clinical improvement on treatment. Seven patients showed improvement in lymphocyte transformation (group A), while the other 7 (group B) showed depression (Figs. 3 and 4) . By definition group A had a significantly greater PHA response at 4 and 16 weeks than at time 0 (P<0 005), and group B had a significantly depressed PHA response (P < 0 * 05). Group A mitogen responses before levamisole were significantly lower than those of group B (P < 0 -0025) ( Table 4 ). The patients in We noted a more consistent response to SK-SD than 3 other skin test antigens; in other studies SK-SD has also been found to be the more sensitive index of depressed CMI in RA (Andrianakos et al., 1977) . (Dieppe et al., 1976a) , whereas antiinflammatory effects occur after prolonged pretreatment (Dieppe et al., 1976b) . Selective enhancement of deficient suppressor T cell lymphocyte activity or macrophage function has been suggested but not demonstrated directly. In its delayed onset of action in RA and its failure to ameliorate adjuvant arthritis (Trabert et al., 1976) levamisole resembles penicillamine (Liyanage and Currey, 1972) and gold (Jessop and Currey, 1968) . Since one levamisole metabolite is a mercaptan (Symoens, 1976) , it is possible that a chelating action by free sulfhydryl groups may account for its therapeutic effect.
In common with gold and penicillamine there is a high primary response rate with levamisole, but during prolonged treatment of RA considerable attrition occurs due to both adverse effects and secondary relapses. In our experience, rash has been the main reason for discontinuation, but granulocytopenia has been reported frequently by others . Almost one-third of our patients who responded initially developed recurrent disease while on continued treatment. The future role of levamisole as a therapeutic agent in RA may depend on more precise definition of optimal doses and treatment schedules and of the clinical characteristics of patients who respond favourably or experience adverse effects. The identification of immunological tests which correlate with and predict these results would also be valuable. 
